Vaccination with NH36 DNA has proven to induce protection against murine cutaneous and visceral leishmaniasis (19–25) as well as against canine VL (26, 27) mediated by a CD4+ T-cell-dependent interferon (IFN)-γ response (21). The gene discussed is IFNG; the disease is visceral leishmaniasis.